Collaborations | Deals


Heptares has signed deals with leading pharmaceutical partners on small molecule and antibody discovery and development programmes in multiple therapeutic areas.

Pipeline Deals


Global R&D and commercialisation agreement (2016) under which Allergan licenses exclusive global rights to Heptares’ broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological diseases, including Alzheimer’s disease. Heptares received $125 million upfront, and is eligible for milestone payments of up to approximately $3.25 billion, plus up to double-digit royalties.

Allergan is also committing up to $50 million to joint R&D programme aimed at advancing multiple candidates through Phase 2 studies. Allergan will be responsible for the development of licensed compounds upon initiation of Phase 2b studies and for subsequent manufacturing and commercialization of the products.

In 2017, the Agreement was amended with Sosei/Heptares gaining rights to develop an M1 agonist (HTL0018318) for Dementia with Lewy Bodies (DLB) in Japan.


Agreement (2015) to develop novel immuno-oncology treatments for a range of cancers. AstraZeneca gains exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds. AstraZeneca will focus on exploring HTL-1071 and any additional compounds across a range of cancers, including in combination with its existing portfolio of immunotherapies.

Heptares received $10 million upfront and is eligible to receive additional, significant near term milestone payments based on agreed pre-clinical and/or clinical events. Subject to successful completion of development and commercialisation milestones, Heptares is also eligible to receive more than $500 million, as well as up to double-digit tiered royalties on net sales.


Strategic collaboration (2016) to discover, develop and commercialise novel antibody therapeutics targeting GPCR immuno-oncology targets.

Heptares will apply its StaR® platform to create stable antigens based on multiple selected GPCR targets. Kymab will use its Kymouse™ discovery platform to generate antibodies in response to immunisation with these antigens. Promising leads will be jointly progressed using complementary skills, resources and development capabilities in order to bring innovative products into the clinic.

Technology Partnerships


Strategic drug discovery collaboration with Pfizer to research and develop potential new medicines (small molecules and biologics) directed at up to 10 GPCR targets across multiple therapeutic areas.

Heptares is eligible to receive potential research, development, regulatory and commercial milestone payments of up to $189 million per target, potential tiered royalties on the net sales of any products that are commercialised by Pfizer. In addition, Pfizer made a $33 million investment in Sosei Group at a 25% premium to preceding 20-day average closing price.


Long-term collaboration (started in 2011) focused on the discovery and development of potential new medicines targeting specific GPCR targets linked to CNS/pain, cardiovascular/metabolic and inflammatory disorders.

AstraZeneca gains worldwide commercial rights to product candidates emerging from the collaboration and will be responsible for preclinical and clinical development. Heptares received $6.25m in cash up front plus committed research funding and is eligible to receive future payments up to $180m in milestones, plus royalties on sales of all products discovered through the collaboration.


Heptares and MedImmune entered a multi-target alliance to deliver StaR protein for defined GPCR targets as antigen for antibody discovery as part of the 2011 deal signed with AstraZeneca (above).

Heptares has received upfront, research and milestone payments, and is eligible for further payments as programmes advance.

Daiichi Sankyo

In 2017, Heptares entered a drug discovery and licensing agreement with Daiichi Sankyo focused on a single GPCR target nominated by Daiichi Sankyo that plays a crucial role in relieving pain.

Daiichi Sankyo will receive exclusive global rights to novel, small molecules discovered by Heptares focused on the nominated GPCR. Heptares will receive $4 million upfront, research funding of approximately $8 million, and is eligible to receive additional research, development and commercialization milestone payments, plus royalties.


In 2013, Heptares and MorphoSys announced an agreement to discover and develop novel antibody candidates targeting a defined set of GPCR targets proposed by MorphoSys. Heptares will generate StaR proteins for the targets and MorphoSys will apply its Ylanthia antibody library to these proteins.

Heptares will receive upfront and research funding payments, plus a share of future sublicensing revenue or milestones and royalties. Heptares also retains rights to develop and commercialise antibody therapeutics created by MorphoSys against a GPCR target to be selected by Heptares.

Heptares exercised an option to initiate a therapeutic antibody programme arising from this alliance in July 2015. The programme will leverage MorphoSys’ Ylanthia® antibody library to generate novel antibody leads and address a GPCR target selected by Heptares, for which Heptares has engineered a StaR antigen. MorphoSys will receive a licensing fee and R&D funding from Heptares and is eligible to receive milestone payments and royalties on the sales of any therapeutic antibodies resulting from the program. Further financial details were not disclosed.

In 2015, Heptares Therapeutics Zurich (formerly G7 Therapeutics) signed a similar agreement with MorphoSys to collaborate on novel antibody therapeutics targeting GPCRs and potentially other disease-related transmembrane proteins, such as ion channels.

© 2012-2018 Heptares Therapeutics